Skip to main content
CivicGate

HRES 685
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.

Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.

Introduced Sep 9, 2025

Latest action (Sep 9, 2025) Referred to the House Committee on Energy and Commerce.

Referred to
Energy and Commerce Committee
Policy area
Health
Issues
Healthcare

Summary
  • Expresses the House of Representatives' support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening.
  • Calls upon professional medical associations and guideline-setting bodies to update their recommendations to include testing for APS as a standard part of prenatal screening.

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)
8 cosponsors

Money behind the sponsor

Top reported contributors to Kat Cammack’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.

  • Employer not reported $148,814
  • ANDREESSEN HOROWITZ $19,800
  • GLEIM PUBLICATIONS $18,600
  • UF $10,436
  • FREY FARMS $10,306

Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Kat Cammack → · Outside spending →

Actions (2)
  1. Sep 9, 2025 Referred to the House Committee on Energy and Commerce. · house
  2. Sep 9, 2025 Submitted in House

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

  • HR 8260 — Cardiovascular Disease Early Detection and Prevention Act of 2026 · Introduced Apr 14, 2026 · Cong. 119 56%
  • HR 9061 — PREEMPT Act · Introduced May 29, 2026 · Cong. 119 52%
  • HRES 611 — Expressing the importance of accurate information for medical professionals treating pregnant women and their unborn children in the emergency department, and for informing the general public, and for other purposes. · Introduced Jul 25, 2025 · Cong. 119 51%
  • HR 6130 — ASAP Act · Introduced Sep 16, 2026 · Cong. 119 50%
  • HR 4709 — Newborn Screening Saves Lives Reauthorization Act of 2025 · Introduced Sep 10, 2025 · Cong. 119 50%
  • HR 820 — Bottles and Breastfeeding Equipment Screening Enhancement Act · Introduced Jul 10, 2025 · Cong. 119 49%

Full text

IN THE HOUSE OF REPRESENTATIVES

September 9, 2025

Mrs. Cammack (for herself, Ms. Kamlager-Dove, Mrs. Kim, Ms. Pettersen, Mrs. Hinson, Ms. Adams, Mrs. Cherfilus-McCormick, and Mr. Landsman) submitted the following resolution; which was referred to the Committee on Energy and Commerce

RESOLUTION

Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.

Whereas antiphospholipid syndrome (APS) is a condition in which the immune system of an individual mistakenly produces antibodies that increase the risk of blood clots; Whereas APS can increase the risk of miscarriages, stillbirths, and pregnancy complications; Whereas professional medical associations and guideline-setting bodies do not recommend testing for APS as a standard part of prenatal screening; Whereas professional medical associations and guideline-setting bodies recommend testing for APS only if a woman has an unexplained fetal loss after 10 weeks or 3 or more unexplained embryonic losses (miscarriages); Whereas APS is responsible for about 15 percent of recurrent pregnancy losses; Whereas the total number of miscarriages caused by APS is unknown because it is not tested as part of normal prenatal screening; Whereas APS can be detected by a blood test and treated by blood thinners; and Whereas testing for APS during normal prenatal screening can save babies and reduce grief for women and families: Now, therefore, be it Resolved, That the House of Representatives—

(1) supports testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening; and

(2) calls upon professional medical associations and guideline-setting bodies to update their recommendations to include testing for APS as a standard part of prenatal screening. <all>

Comments

Comments

Loading comments…